CA2530460A1 - Procede de traitement du syndrome coronarien aigu - Google Patents
Procede de traitement du syndrome coronarien aigu Download PDFInfo
- Publication number
- CA2530460A1 CA2530460A1 CA002530460A CA2530460A CA2530460A1 CA 2530460 A1 CA2530460 A1 CA 2530460A1 CA 002530460 A CA002530460 A CA 002530460A CA 2530460 A CA2530460 A CA 2530460A CA 2530460 A1 CA2530460 A1 CA 2530460A1
- Authority
- CA
- Canada
- Prior art keywords
- therapeutic agent
- group
- formulation
- encapsulated
- bisphosphonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000004476 Acute Coronary Syndrome Diseases 0.000 title claims abstract 8
- 238000000034 method Methods 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract 25
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 25
- 239000000203 mixture Substances 0.000 claims abstract 16
- 238000009472 formulation Methods 0.000 claims abstract 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 9
- 210000001539 phagocyte Anatomy 0.000 claims abstract 6
- 206010000891 acute myocardial infarction Diseases 0.000 claims abstract 5
- 230000007423 decrease Effects 0.000 claims abstract 4
- 206010002388 Angina unstable Diseases 0.000 claims abstract 3
- 208000007814 Unstable Angina Diseases 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims abstract 3
- 210000002540 macrophage Anatomy 0.000 claims abstract 3
- 210000001616 monocyte Anatomy 0.000 claims abstract 3
- 229940122361 Bisphosphonate Drugs 0.000 claims 8
- 150000004663 bisphosphonates Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 3
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 3
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims 3
- 229940062527 alendronate Drugs 0.000 claims 3
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 3
- 229960002286 clodronic acid Drugs 0.000 claims 3
- 239000000084 colloidal system Substances 0.000 claims 3
- 229940009626 etidronate Drugs 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 239000011859 microparticle Substances 0.000 claims 3
- 239000004005 microsphere Substances 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 239000002077 nanosphere Substances 0.000 claims 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 3
- 229940046231 pamidronate Drugs 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229940019375 tiludronate Drugs 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- -1 chlorosubstituted phenyl Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 150000003512 tertiary amines Chemical class 0.000 claims 2
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/607,623 | 2003-06-27 | ||
| US10/607,623 US10517883B2 (en) | 2003-06-27 | 2003-06-27 | Method of treating acute myocardial infarction |
| US10/871,488 US9498488B2 (en) | 2003-06-27 | 2004-06-18 | Method of treating acute coronary syndromes |
| US10/871,488 | 2004-06-18 | ||
| PCT/US2004/020487 WO2005002545A1 (fr) | 2003-06-27 | 2004-06-24 | Procede de traitement du syndrome coronarien aigu |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2530460A1 true CA2530460A1 (fr) | 2005-01-13 |
| CA2530460C CA2530460C (fr) | 2012-08-14 |
Family
ID=33568009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2530460A Expired - Fee Related CA2530460C (fr) | 2003-06-27 | 2004-06-24 | Procede de traitement du syndrome coronarien aigu |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP4621202B2 (fr) |
| AU (1) | AU2004253527B2 (fr) |
| CA (1) | CA2530460C (fr) |
| WO (1) | WO2005002545A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060051407A1 (en) * | 2003-06-27 | 2006-03-09 | Yoram Richter | Method of treating ischemia-reperfusion injury |
| US10517883B2 (en) | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
| JP4992091B2 (ja) * | 2005-02-17 | 2012-08-08 | ハダシット メディカル リサーチ サービシーズ アンド デベロップメント リミテッド | 子宮内膜症を治療するためのビスホスホネート |
| EP2279726A3 (fr) * | 2005-05-26 | 2012-06-20 | Biorest Ltd. | Compositions et méthodes d'utilisation desdites compositions dans l'administration d'agents dans un organe cible protégé par une barrière sanguine |
| ES2537216T3 (es) * | 2009-09-01 | 2015-06-03 | Duke University | Composiciones de bisfosfonato y métodos para tratar la insuficiencia cardíaca |
| JP6261512B2 (ja) | 2011-11-16 | 2018-01-17 | デューク ユニバーシティ | 心機能障害を治療及び／又は低減するためのビスホスホネート組成物並びに方法 |
| US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| CN106456775A (zh) * | 2014-05-16 | 2017-02-22 | 生物休眠有限公司 | 双膦酸盐作为hiv/aids辅助治疗的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6139871A (en) * | 1995-07-26 | 2000-10-31 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
| AU7525296A (en) * | 1995-11-01 | 1997-05-22 | Chiron Corporation | Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space |
| DE19637890A1 (de) * | 1996-09-17 | 1998-03-19 | Max Planck Gesellschaft | Biphosphonat-Liposomen |
| IL125336A0 (en) * | 1998-07-14 | 1999-03-12 | Yissum Res Dev Co | Compositions for inhibition and treatment of restinosis |
| CN1635910A (zh) * | 2001-05-02 | 2005-07-06 | 普渡研究基金会 | 巨噬细胞介导的疾病的治疗和诊断 |
-
2004
- 2004-06-24 AU AU2004253527A patent/AU2004253527B2/en not_active Ceased
- 2004-06-24 WO PCT/US2004/020487 patent/WO2005002545A1/fr active Application Filing
- 2004-06-24 CA CA2530460A patent/CA2530460C/fr not_active Expired - Fee Related
- 2004-06-24 JP JP2006517683A patent/JP4621202B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2530460C (fr) | 2012-08-14 |
| JP4621202B2 (ja) | 2011-01-26 |
| WO2005002545A8 (fr) | 2006-02-16 |
| AU2004253527A1 (en) | 2005-01-13 |
| JP2007524632A (ja) | 2007-08-30 |
| AU2004253527B2 (en) | 2010-04-08 |
| WO2005002545A1 (fr) | 2005-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2596679A1 (fr) | Procede de traitement de lesion d'ischemie-reperfusion | |
| Chakraborti et al. | Drug intercalation in layered double hydroxide clay: Application in the development of a nanocomposite film for guided tissue regeneration | |
| CN1277545C (zh) | 二膦酸类化合物在制备用于治疗与前列腺癌有关的骨转移瘤的药物中的用途 | |
| EP3116547B1 (fr) | Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation | |
| JP2010531879A5 (fr) | ||
| CZ20014289A3 (cs) | Nové pouľití sloučenin jako antibakteriálních činidel | |
| CA2369560A1 (fr) | Medicaments destines a soigner et a prevenir les maladies du foie | |
| CA2597699A1 (fr) | Bisphosphonates pour le traitement de l'endometriose | |
| NZ527157A (en) | Compositions for delivering bisphosphonates | |
| CA2410311A1 (fr) | Analogues de l'acide barbiturique utilises comme agents therapeutiques | |
| WO2006019843A1 (fr) | Procedes et compositions pour l'administration de chelateurs de calcium, de biphosphonates et/ou de composes de citrate et leurs utilisations pharmaceutiques | |
| CY1110949T1 (el) | Σταθεροποιημενες με πηκτωμα συνθεσεις νανοσωματιδιακων δραστικων παραγοντων | |
| CA2530460A1 (fr) | Procede de traitement du syndrome coronarien aigu | |
| RU2007137846A (ru) | Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц | |
| JP2008538751A5 (fr) | ||
| WO2013075394A1 (fr) | Vecteur de médicament à micelle composite chélatrice et son utilisation | |
| HUP0202781A2 (hu) | Béta-karbolin szemcsés formája, ezt tartalmazó gyógyszerkészítmények, előállításaik és alkalmazásuk | |
| US20130012589A1 (en) | Stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone | |
| ES2872552T3 (es) | Nanopartículas poliméricas y métodos de preparación y de uso de las mismas | |
| CA2438509A1 (fr) | Utilisation de derives de cyclohexenone pour la preparation d'un medicament permettant de traiter la dysurie | |
| AU2017252122A1 (en) | Use of Thyroid beta-Agonists | |
| JP2009280500A (ja) | リン酸カルシウム結合性リポソーム | |
| CA2556756A1 (fr) | Methodes et compositions d'administration de promedicaments d'inhibiteurs de la pompe a protons | |
| US9701646B2 (en) | Small molecule inhibitors of PI3-kinase signaling | |
| CA2635356A1 (fr) | Utilisation de la 1,3,5-triazepin-2,6-dione contre le paludisme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20200831 |